Drug Trial Radar · NCT04689828
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
469
Actual
Start
Jun 15, 2021
Primary completion
Oct 2, 2022
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. 469 participants were randomized (235 in the 177Lu-PSMA-617 group and 234 in the ARDT group.
Conditions
- Prostatic Neoplasms
Interventions
177Lu-PSMA-617Drug
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
68Ga-PSMA-11Drug
single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
ARDTDrug
administered orally on a continuous basis, as per package insert and guidelines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression Free Survival (rPFS)Time frame: median FU (randomization to event or censoring) 3.65 months (range 0-12.3)
Locations
72 sites in 14 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers
Denver, Colorado
University of Florida
Gainesville, Florida
Tulane Uni Health Sciences Center
New Orleans, Louisiana
Dana Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Med Ctr
Boston, Massachusetts
WA Uni School Of Med
St Louis, Missouri
Urology Cancer Center PC
Omaha, Nebraska
Nebraska Cancer Specialists
Omaha, Nebraska
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York
Mount Sinai Hosp Med School
New York, New York
Memorial Sloan Kettering Cancer Ctr
New York, New York
Duke Univ Medical Center
Durham, North Carolina
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Tennessee Oncology
Nashville, Tennessee
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Virginia Oncology Associates
Norfolk, Virginia
Onco Hemato Asso of SW Virginia
Roanoke, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Medical College Of Wisconsin
Milwaukee, Wisconsin
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Roeselare, West-Vlaanderen, Belgium
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Angers, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Nijmegen, Netherlands
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.